Director Rafael De La Vega filed a Form 4 with the SEC on November 16, 2026, disclosing a purchase of Amdocs Ltd ordinary shares on November 12, 2026.
Xtant Medical Holdings, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 16, 2026, disclosing operational details, strategic developments, and a share count of 140,452,061 as of November 13, 2026.
Barrel Energy, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 16, 2026, reporting a net loss of $1,518,216 for the nine months ended September 30, 2026.
Prelude Therapeutics Incorporated filed its quarterly report on Form 10-Q with the SEC on November 16, 2026, covering the three and nine months ended September 30, 2026.
Instil Bio, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 16, 2026, disclosing a net loss of $4.231 million for the third quarter and $13.023 million for the nine months ended September 30, 2026.
Translational Development Acquisition Corp. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 16, 2026, reporting a net loss of $9,293,622 for the third quarter and disclosing a new $10,200,000 Subscription Agreement liability on its balance …
Xtend AI Robotics, Inc. filed a Form 8-K with the SEC on November 16, 2026, announcing its financial results for the quarter ended September 30, 2026, with the full press release furnished as Exhibit 99.1.
TheReversalfollowed a powerful run. The shares were up almost 5% over the past week and nearly 20% over the past month heading into Friday, and the broader market was also under pressure. AerCap's chief executive recently sold shares worth more than $9.4 million, a …
The gas market was the main headwind. U.S. natural gas futures fell about 3% to around $3.23 per million British thermal units after the Energy Information Administration reported a 61 billion cubic foot storage injection for the week ended November 6. That took Lower …
The stock is still working through its third-quarter report on November 9 and a round of price-target reductions on November 10. Mizuho cut its target to $9 from $11 while keeping an Outperform rating, Canaccord Genuity trimmed its target to $12 from $15 with …